> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Andexxa sBLA
- URL: https://www.fdaweb.com/panel-to-review-andexxa-sbla/
- Published: 2024-10-01T12:00:00.000Z
- Updated: 2026-09-14T14:42:55.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157892

*Federal Register* notice: FDA is announcing an 11/21 Cellular, Tissue, and Gene Therapies Advisory Committee meeting to review an AstraZeneca supplemental BLA for Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). The submission is seeking approval for the biologic’s use in patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-22561.pdf?ref=fdaweb.com).